Ariella Hanker, Associate Professor at UT Southwestern Medical Center, shared ILC Symposium’s post on LinkedIn, adding:
”Excited to participate in the ILC Symposium in San Francisco next month! Many of the genomic alterations I study – including HER2, NF1/KRAS, and PIK3CA – are enriched in invasive lobular breast cancers, particularly metastatic, treatment-resistant tumors. Why are ILCs especially susceptible to genomic activation of growth factor signaling pathways, and does this create actionable therapeutic vulnerabilities?”
Quoting ILC Symposium‘s post:
”We are excited to share that registration is open for the 7th Biannual International Invasive Lobular Carcinoma (ILC) Symposium, taking place September 23–25, 2026 in San Francisco, CA.
The symposium brings together clinicians, scientists, and patient advocates to share the latest discoveries, exchange ideas, and build collaborations that move the field forward.
This meeting offers an outstanding opportunity to:
- Discover the latest advances in ILC research
- Connect with colleagues from around the world
- Spark new collaborations across disciplines
- Engage with emerging investigators and the next generation of ILC researchers
September 23–25, 2026
Hyatt Regency San Francisco
Learn more and register.
Please share with colleagues, collaborators, and trainees who may be interested. We look forward to seeing many of you in San Francisco this September!”
Other articles about Cancer types on OncoDaily.